Gilead ponders Sovaldi price break

Share this article:

Antiviral drugmaker Gilead is rumored to be in price negotiations in India for its new hep. C pill Sovaldi (sofosbuvir). The Hindu Business Line reports that the biotech is looking to introduce Sovaldi into India's marketplace.

Twelve weeks of the treatment costs $84,000 in the US, but the framework for a deal in India is far different: the company is said to be looking to price its locally produced version of the medication at around $2,000 for six months of therapy. The company is in talks with patient advocacy groups.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies